Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc (NY: CYBN )

10.38 +0.13 (+1.27%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
38 39 Next >
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.48% at $0.14 
Via Benzinga
Cybi (NEO: CYBN) (NYSE American: CYBN) To Participate In Benzinga Psychedelics Conference
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybi (NEO: CYBN) (NYSE American: CYBN) to Participate in Benzinga Psychedelics Conference
Via Investor Brand Network
Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 4.78% at $19.73 LOSERS: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference
Via Investor Brand Network
A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers
From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE: CYBN) CEO, Doug Drysdale has certainly had an ... 
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From April 5, 2022
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 1.60% at $1.27 LOSERS: 
Via Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.06% at $14.18 
Via Benzinga
Cybin's (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
Via Investor Brand Network
3 Psychedelic Stocks to Buy for Oregon’s Magic Mushroom Bill
Psychedelic medical treatments and therapies are gaining in popularity, and these psychedelic stocks could benefit as the market emerges. 
Via InvestorPlace
Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.26% at $0.86 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement Of Kernel Flow(R) Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Inc. Achieves New Milestone
Via Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Study
Via Investor Brand Network
March Update: Psychedelic Compounds-Based Drug Stocks Index Went Down -19%
An update on the revisions that have been made to the Pure-Play Psychedelic Compounds-Based Drug Stocks Index with the increase in the minimum market capitalization required to be included in the... 
Via Talk Markets
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Field Trip Health, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 3.38% at $0.27 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development
Via Investor Brand Network
Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain
The first study visit to measurethe psychedelic effects of ketamine in the cerebral cortex blood flowis underway, ... 
Via Benzinga
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 4.22% at $0.46 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone In CYB003 Program
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone in CYB003 Program
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From March 29, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 9.05% at $5.42 
Via Benzinga
Cybin Completes In Vivo Preclinical Studies For Major Depressive Disorder
Cybin Inc.(NYSE: CYBN) announced that its in vivo preclinical studies evaluating the proprietary drug CYB003 are completed. ... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program
Via Investor Brand Network
New Research Reveals How Psychedelics Are Helping Combat Mental Illness
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily,... 
Via FinancialNewsMedia
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.